Stock Region Penny Picks
đ Stock Region Watchlist: The Thursday Thriller
đ Stock Region Penny Picks Watchlist: The Thursday Thriller
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Regionâs real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following information is for educational and entertainment purposes only. I am not a financial advisor, and nothing in this newsletter constitutes financial advice. Trading stocks involves risk, and you can lose money. Always do your own due diligence before making any investment decisions.
Whatâs up, Stock Region family!
It is officially Thursday, January 9th, and if youâre like me, youâre still trying to process the sheer volume of news that dropped yesterday. The market never sleeps, and honestly, neither do we. It feels like 2026 is kicking off with some serious momentum, doesnât it? Thereâs this electric buzz in the airâcompanies are finally shaking off the dust and making big moves.
Todayâs watchlist is packed with some heavy hitters and a few underdogs that are suddenly barking loud. Letâs dive into the madness.
đĽ $ACON - Aclarion: The Comeback Kid?
First up, letâs talk about Aclarion ($ACON). They dropped an update yesterday regarding their 2025 performance and 2026 outlook, and wow. We are talking about a 114% increase in scan volumes for Q4 year-over-year.
But hereâs the kicker that really got me excited: they are debt-free with $12 million in cash. In this economic climate? That is huge. It extends their runway into 2027. My opinion? A debt-free biotech/medtech company with triple-digit growth metrics is rare. Keep a close eye on this one; financial flexibility usually precedes big moves.
âď¸ $SKYX - SKYX Platforms: Nvidia? Yes, Please.
Okay, anytime I see the word âNVIDIAâ in a headline, my ears perk up. SKYX Platforms ($SKYX) announced a collaboration with NVIDIA for their smart home platform.
They are integrating into NVIDIAâs AI ecosystem. This feels like a massive validation of their tech. We all know AI is the kingmaker right now, and if SKYX can leverage NVIDIAâs cloud capabilities effectively, their ceiling smart platforms might just become the standard. This is a âwatch closelyâ play for me.
đ° $ALTS - ALT5 Sigma: Show Me the Money
Records are meant to be broken, and ALT5 Sigma ($ALTS) just smashed one. They reported a record annual transaction volume of $3.4 Billion in 2025.
That is a lot of volume. It tells me that their payment and crypto infrastructure is actually being used. In a sector full of vaporware, seeing hard numbers like $3.4B is refreshing. It feels like they are scaling quietly but aggressively.
âď¸ $FLYX - flyExclusive: Internet at 30,000 Feet
flyExclusive ($FLYX) signed a dealership agreement with Starlink.
I love this for the customer experience angle. If youâve ever flown private (or aspire to), you know connectivity can be hit or miss. Starlink is basically the gold standard for satellite internet right now. This partnership makes FLYXâs fleet significantly more attractive to business travelers who canât afford to be offline. Smart move.
đĄď¸ $CETX - Cemtrex: Going on the Defense
Cemtrex ($CETX) completed their acquisition of Invocon and is launching an Aerospace & Defense segment.
Defense tech is hot. With geopolitical tensions always simmering, expanding into missile defense modernization is... well, itâs a lucrative pivot. It transforms them from a general tech holding into a defense player. This sector rotates hot and cold, but right now, defense spending isnât slowing down.
⥠Quick Hits & Honorable Mentions
$CNCK (Coincheck): Acquiring 3iQ. Consolidation in the digital asset space usually signals maturity. This is a power move.
$MLTX (MoonLake): Positive outcome from their FDA meeting. Regulatory wins are the lifeblood of biopharma. An Investor Day announcement usually means they have something good to show off.
$NVVE (Nuvve): It was a rollercoaster day for them. First, they regained Nasdaq compliance (yay!), and then later in the day, they filed to cancel an offering (double yay?). Dilution fears canceled? That could squeeze shorts.
$RNXT (RenovoRx): Promising new clinical data coming at ASCO GI 2026. If the data is good, the stock usually follows.
$TIVC (Tivic): Acquired CDMO assets to speed up drug development. Speed is money in this game.
$ARTL (Artelo): Got a patent allowance for solid forms of Cannabidiol. Patents = Moats. Always good to see IP protection.
The theme for this week seems to be Infrastructure and Validation. Whether itâs NVIDIA validating SKYX, the FDA validating MoonLake, or Starlink validating flyExclusiveâpartnerships and regulatory wins are driving the narrative.
Stay sharp out there, team. The market gives, and the market takes. Letâs make sure weâre on the receiving end today.
Happy Trading!
Disclaimer: This newsletter is for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities. The author may hold positions in the stocks mentioned. Investing in the stock market involves significant risks, including the potential loss of your entire investment. Past performance is not indicative of future results. Always consult with a qualified financial advisor before investing.